JP2001515712A5 - - Google Patents

Download PDF

Info

Publication number
JP2001515712A5
JP2001515712A5 JP2000510770A JP2000510770A JP2001515712A5 JP 2001515712 A5 JP2001515712 A5 JP 2001515712A5 JP 2000510770 A JP2000510770 A JP 2000510770A JP 2000510770 A JP2000510770 A JP 2000510770A JP 2001515712 A5 JP2001515712 A5 JP 2001515712A5
Authority
JP
Japan
Prior art keywords
april
use according
blocking agent
suppressing
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000510770A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001515712A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/019191 external-priority patent/WO1999012965A2/en
Publication of JP2001515712A publication Critical patent/JP2001515712A/ja
Publication of JP2001515712A5 publication Critical patent/JP2001515712A5/ja
Pending legal-status Critical Current

Links

JP2000510770A 1997-09-12 1998-09-11 増殖効果を有する新規タンパク質−ａｐｒｉｌ Pending JP2001515712A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
US60/058,786 1997-09-12
US7938498P 1998-03-26 1998-03-26
US60/079,384 1998-03-26
PCT/US1998/019191 WO1999012965A2 (en) 1997-09-12 1998-09-11 April- a novel protein with growth effects

Publications (2)

Publication Number Publication Date
JP2001515712A JP2001515712A (ja) 2001-09-25
JP2001515712A5 true JP2001515712A5 (https=) 2006-01-05

Family

ID=26738027

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000510770A Pending JP2001515712A (ja) 1997-09-12 1998-09-11 増殖効果を有する新規タンパク質−ａｐｒｉｌ

Country Status (20)

Country Link
US (3) US20030138884A1 (https=)
EP (1) EP1027431A2 (https=)
JP (1) JP2001515712A (https=)
KR (1) KR100618492B1 (https=)
CN (1) CN1195849C (https=)
AU (1) AU759717B2 (https=)
BR (1) BR9812634A (https=)
CA (1) CA2303615A1 (https=)
CZ (1) CZ294615B6 (https=)
EA (1) EA005411B1 (https=)
EE (1) EE200000147A (https=)
HU (1) HUP0004611A3 (https=)
IL (1) IL134537A0 (https=)
IS (1) IS5378A (https=)
NO (1) NO20001242L (https=)
NZ (1) NZ503850A (https=)
PL (1) PL339463A1 (https=)
SK (1) SK3542000A3 (https=)
TR (1) TR200000669T2 (https=)
WO (1) WO1999012965A2 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
AU5201399A (en) * 1997-09-30 1999-10-18 Pharmacia & Upjohn Company Tnf-related death ligand
WO1999026976A1 (en) * 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
WO2001060397A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
IL144202A0 (en) 1999-01-25 2002-05-23 Biogen Inc Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
CN100447244C (zh) 1999-08-17 2008-12-31 比奥根艾迪克Ma公司 Baff受体(bcma),一种免疫调节剂
WO2001025256A2 (en) * 1999-10-06 2001-04-12 University Of Utah Research Foundation Trdl-1-gamma, a novel tumor necrosis-like ligand
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2897626C (en) 2000-02-11 2020-03-24 Biogen Ma Inc. Heterologous polypeptide of the tnf family
AU2006201471B2 (en) * 2000-02-16 2009-07-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
WO2001087977A2 (en) * 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP2431054A3 (en) * 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
GB2370273A (en) * 2000-12-20 2002-06-26 Viaxxel Biotech Gmbh Compounds that affect CD83 expression
BRPI0209933B8 (pt) 2001-05-24 2021-05-25 Zymogenetics Inc proteína de fusão, e, molécula de ácido nucleico
EP1401870A4 (en) 2001-05-24 2006-04-19 Human Genome Sciences ANTIBODIES AGAINST TUMOR NECROSIS FACTOR DELTA (APRIL)
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
US20030166559A1 (en) 2002-01-04 2003-09-04 Desjarlais John R. Dominant negative proteins and methods thereof
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
WO2004089982A2 (en) * 2003-01-06 2004-10-21 Xencor April variants and methods thereof
US7700317B2 (en) 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
US20070249530A1 (en) * 2004-01-29 2007-10-25 Genentech, Inc. Bcma Polypeptides and Uses Thereof
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2005113598A2 (en) * 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
US7947805B2 (en) 2004-12-23 2011-05-24 Merck Serono S.A. BCMA polypeptides and uses thereof
EP1922080A2 (en) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for treating b-cell malignancies using taci-ig fusion molecule
WO2007019573A2 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
EP1934258B1 (en) * 2005-09-26 2011-03-02 Enzo Life Sciences (ELS) AG Antibodies against april as biomarkers for early prognosis of lymphoma patients
WO2007142667A2 (en) 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
ES2618543T3 (es) 2005-11-23 2017-06-21 Genentech, Inc. Métodos y composiciones relacionados con ensayos de linfocitos B
BRPI0711823A2 (pt) 2006-05-15 2012-01-17 Ares Trading Sa métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
CA2754127C (en) 2009-03-02 2017-04-18 Stichting Top Institute Pharma Antibodies against a proliferating inducing ligand (april)
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
EP2542679A1 (en) * 2010-03-05 2013-01-09 Academisch Medisch Centrum bij de Universiteit van Amsterdam B-cell stimulating fusion proteins of an antigen with baff or april
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
TR201901782T4 (tr) * 2013-09-23 2019-03-21 Regeneron Pharma İnsanlaştirilmiş bi̇r si̇nyal düzenleyi̇ci̇ protei̇n geni̇ne sahi̇p olan i̇nsan dişi hayvanlar.
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
RU2671101C1 (ru) * 2013-11-19 2018-10-29 Регенерон Фармасьютикалс, Инк. Отличные от человека животные, содержащие гуманизированный ген индуцирующего пролиферацию лиганда
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
FI3380522T3 (fi) 2015-11-25 2024-01-16 Visterra Inc Vasta-ainemolekyylejä april-proteiinille ja niiden käyttöjä
EP4237121A1 (en) 2020-10-29 2023-09-06 Industrial Polymers and Chemicals, Inc. Air filter with pathogen monitoring and inactivation
KR20240053675A (ko) 2021-08-11 2024-04-24 악소 바이오파마슈티컬 인코포레이티드 sBCMA 변이체 및 이의 FC 융합 단백질을 이용한 IgA, IgM 및/또는 IgG의 생산 감소 방법
AU2024239150A1 (en) 2023-03-21 2025-10-02 Biograph 55, Inc. Cd19/cd38 multispecific antibodies
CN118909083A (zh) * 2024-07-30 2024-11-08 江苏省农业科学院 一种猪b细胞增殖诱导配体蛋白及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) * 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
WO1996040774A1 (en) * 1995-06-07 1996-12-19 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical preparations
US6509170B1 (en) * 1996-03-14 2003-01-21 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor delta
AU726486C (en) * 1996-03-14 2004-02-05 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US6171787B1 (en) * 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease

Similar Documents

Publication Publication Date Title
JP2001515712A5 (https=)
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
PL287844A1 (en) Method of obtaining an oraly administered composite medicine for treating interstinal inflamatory diseases
HK1043313A1 (zh) 用於治疗癌症的多西他赛和rhumab her2
RU2002127804A (ru) Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения
CA2334267A1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
CA2214503A1 (en) Method for treating tumors
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
IL161889A (en) Use of omega interferon in the manufacture of a medicament for treating viral disease
WO2003049694A3 (en) Methods of therapy for non-hodgkin's lymphoma
JP2004537500A5 (https=)
WO2000040229A3 (en) Synergistic tumorcidal response induced by histamine
WO2000008007A3 (de) Cyclopentabenzofuran-derivate und ihre verwendung
Zein Interferons in the management of viral hepatitis
EP1561462A3 (en) Anti arrhytmic composition and methods of treatment
CA2091134A1 (en) Therapeutic agent for threatened abortion
MY105798A (en) Treatment of leukocyte dysfunction with gm-csf.
EP0795332A3 (en) Medical use of gamma-interferon in interstitial lung diseases
Corazziari Need of the ideal drug for the treatment of chronic constipation
WO2001045642A3 (en) Pulmonary delivery of ribavirin or levovirin™ for systemic and quasi-systemic treatment of disease
JP2002520292A5 (ja) ヒト成長因子と組み合わせた脈管形成剤としてのコンポーネントｂの使用
RU2000103385A (ru) Способ лечения острого панкреотита
EP0408525A3 (en) Use in therapy of 10-amino-5,6-dihydro-11h-dibenzo(b,e)azepine-6,11-dione and derivatives as drugs for use in the treatment of urinary incontinence
CN1053577C (zh) 烧烫散